Triheptanoin

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glucose Transporter Type 1 Deficiency Syndrome

Conditions

Glucose Transporter Type 1 Deficiency Syndrome

Trial Timeline

Apr 1, 2014 → Oct 1, 2016

NCT ID

NCT02000960

About Triheptanoin

Triheptanoin is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Glucose Transporter Type 1 Deficiency Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT02000960. Target conditions include Glucose Transporter Type 1 Deficiency Syndrome.

What happened to similar drugs?

4 of 6 similar drugs in Glucose Transporter Type 1 Deficiency Syndrome were approved

Approved (4) Terminated (3) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Candesartan + PlaceboAstraZenecaApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

❌UX007 + PlaceboUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01461304	Pre-clinical	Completed	—	—	Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
NCT02968953	Pre-clinical	Completed	—	—	Glucose Transporter 1 Deficiency Syndrome
NCT03773770	Pre-clinical	Active	—	—	Long Chain Fatty Acid Oxidation Disorders
NCT07097311	Phase 2	Recruiting	Jul 1, 2026	Apr 1, 2028	Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06067802	Phase 2	Active	Feb 1, 2026	Jul 1, 2028	Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06340685	Phase 1	Recruiting	Jul 11, 2024	Jun 30, 2029	Pyruvate Dehydrogenase Complex Deficiency
NCT05933200	Phase 3	Active	Feb 28, 2023	Aug 1, 2027	Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
NCT03665636	Phase 1	Completed	Oct 16, 2020	Oct 21, 2021	Glycogen Storage Disease Type I
NCT03506425	Phase 1/2	Completed	Jun 21, 2018	Mar 28, 2019	ALS
NCT02696044	Phase 2	UNKNOWN	Jun 1, 2016	Feb 1, 2022	Rett Syndrome
NCT02432768	Phase 2	Completed	Apr 1, 2015	Feb 1, 2019	Glycogen Storage Disease Type V
NCT02000960	Phase 2	UNKNOWN	Apr 1, 2014	Oct 1, 2016	Glucose Transporter Type 1 Deficiency Syndrome
NCT02036853	Phase 2	Completed	Feb 20, 2014	Jun 30, 2019	Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
NCT00947960	Phase 2	Completed	Jun 1, 2009	Jul 1, 2015	Adult Polyglucosan Body Disease

Competing Products

17 competing products in Glucose Transporter Type 1 Deficiency Syndrome

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
AZD1656	AstraZeneca	Phase 1	29
Candesartan + Placebo	AstraZeneca	Approved	35
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg	Merck	Phase 2	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007	Ultragenyx Pharmaceutical	Phase 2	21
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 3	26
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25